ICT-107 Boosts Overall Survival by 10 Percent In Phase II Glioblastoma Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Updated overall survival results and immune response data a phase II trial of ICT-107 in patients with newly diagnosed glioblastoma demonstrated a survival advantage compared to the control group.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login